Chelsea ANDA withdrawals
FDA is proposing to withdraw nine ANDAs of the West Hempstead, New York-based generics manufacturer on the grounds that the applications contained untrue statements and that the products are not safe and effective. The ANDAs include verapamil 80 mg and 120 mg tablets (Calan), disopyramide 100 mg and 150 mg capsules (Norpace), perphenazine 4 mg/amitriptyline 50 mg tablets (Tiavil), oxazepam 10, 15 and 30 mg tablets (Serax), and perphenzing 8 mg tablets (Tilafon). Chelsea has until July 23 to request a hearing.
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.